Management of Acute Pulmonary Embolism with Right Ventricular Dysfunction

Initial Management and Risk Stratification

The European Society of Cardiology recommends initiating immediate anticoagulation with unfractionated heparin (80 U/kg bolus followed by 18 U/kg/h infusion) while assessing hemodynamic stability to determine if systemic thrombolysis is required 1, 2
Patients with right ventricular dysfunction and pericarditis are at minimum in the intermediate-risk category, with high-risk features including systolic blood pressure <90 mm Hg, need for vasopressor support, or persistent hypotension despite initial resuscitation 1, 2, 3
The presence of high-risk features indicates high-risk (massive) pulmonary embolism with approximately 30% mortality, requiring immediate reperfusion therapy 3

The American Heart Association suggests that hemodynamic support should be initiated cautiously, avoiding aggressive fluid resuscitation and using norepinephrine as the vasopressor of choice for hypotensive patients 1, 2
Dobutamine or dopamine may be considered if cardiac index is low but blood pressure is normal 1, 2
Unfractionated heparin is preferred over low molecular weight heparin in this setting due to its short half-life, allowing rapid reversal if reperfusion therapy becomes necessary 1, 2
The target activated partial thromboplastin time (aPTT) is 1.5-2.5 times normal, corresponding to anti-Xa 0.3-0.6 IU/mL 5

Systemic thrombolysis is the primary treatment for hemodynamically unstable patients (high-risk pulmonary embolism) and is a Class I recommendation for patients with shock or persistent hypotension 4
Surgical embolectomy is an alternative if thrombolysis is contraindicated or has failed 1, 2, 4
Catheter-directed therapy can be considered as an alternative to surgery, particularly if surgical expertise is unavailable 3

Continuous monitoring should include hemodynamic parameters, oxygen saturation, and respiratory status, as well as serial troponin and BNP if initially elevated 3, 4
The minimum anticoagulation duration is 3 months, with extended therapy decisions based on provoked versus unprovoked pulmonary embolism and bleeding risk 1, 2, 6
Direct oral anticoagulants (rivaroxaban or apixaban) can be started directly after 1-2 days of unfractionated heparin, or low molecular weight heparin or fondaparinux can be used overlapping with vitamin K antagonist 1, 2